Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. - Wikidata - wikimedia - TriplyDB

Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.

Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.

http://www.wikidata.org/entity/Q37161532

about

Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study Co-medication of statins with contraindicated drugs.A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.Drug interactions with statins.Drug-drug Interactions of Statins Potentially Leading to Muscle-Related Side Effects in Hospitalized Patients.Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction.Caution is Needed in Designing Pharmacy Coverage.

P2860

Q28535157-7E17A401-796C-4B72-B603-1D687C020F1E Q35561151-B225F51F-4E20-4B82-9088-3A50C900F7B1 Q36203546-FAF6CC93-622F-4CD3-B80A-22B6EC181755 Q36764834-7CDB7014-9841-4784-A6C0-84214662E314 Q37473382-77C0B853-1E16-4DB3-AA34-C8A794C5EDC0 Q38155016-A64C6F3D-3053-4381-94EF-EE3B1178209F Q39950634-5BBA6A6C-FD36-46D3-9979-E95BCA45103E Q41690509-51D5BD00-7E29-45F6-ABAE-4FFEFA516177 Q42334333-7EA38DF8-CD1A-4F80-B415-209B79EE858F

P2860

Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.

http://www.wikidata.org/entity/Q37161532

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Co-medication of statins and C ...... n of new reimbursement policy.

@en

Co-medication of statins and C ...... n of new reimbursement policy.

@nl

type

label

Co-medication of statins and C ...... n of new reimbursement policy.

@en

Co-medication of statins and C ...... n of new reimbursement policy.

@nl

prefLabel

Co-medication of statins and C ...... n of new reimbursement policy.

@en

Co-medication of statins and C ...... n of new reimbursement policy.

@nl

P1433

Q37161532-C32BC2B9-8B07-4A5C-842F-F100227910FE

P1476

Q37161532-AC3F79F7-EAAE-484C-9B1B-69E4878D62C5

P2093

Q37161532-77281214-05B9-4C91-9713-824E8AC5A963

Q37161532-979AF79E-14D3-4D3B-81ED-E3FB68726639

Q37161532-A539FE32-63A9-44CD-9D44-85A636519565

Q37161532-EA55F5C6-2C4E-41C5-B80C-7C67AC973863

P2860

Q37161532-02964757-2361-42DF-880E-6FF101719BEE

Q37161532-11FFC35B-2F71-415F-9AD2-7CA4B92D4300

Q37161532-1F4C3ADE-E92A-44A4-B3B0-8FE77829B0A3

Q37161532-242EC2EC-1C7A-4FBA-A648-8B219AB54C8E

Q37161532-3132D960-6288-42F5-8BC1-A8CFD3D63345

Q37161532-33FA13C6-E9BC-4553-BE2C-9BB0AB177586

Q37161532-4796937D-C60C-44B4-82BD-35D926AD4CAB

Q37161532-4E5D5FA0-BC92-42CF-AF5A-4A3839BE4EC6

Q37161532-4EACE89D-CF73-4292-B94F-C504CE9048CF

Q37161532-57C9C92C-F219-4177-970B-CEC4263FC6EE

P304

Q37161532-66BD11BB-9A93-4D6D-A9C4-1346A6467B7B

P31

Q37161532-D700EC99-9672-4B95-ADED-8CBF2730C123

P356

Q37161532-354939C6-26DE-4A29-B996-2CF9A6F290BC

P407

Q37161532-78460372-BD91-4D5E-B0E6-48A66787C73F

P433

Q37161532-9A5B895D-D05E-4660-B6FA-4DC5BC28F17C

P478

Q37161532-FC490F6D-3CE8-431F-BEA7-8E97704C38BC

P577

Q37161532-8E6A1245-AF30-4353-95D7-50115DA8CF9B

P5875

Q37161532-8A14BA72-780C-4923-A1AB-76E5F14FD0E7

P698

Q37161532-01A09543-08A0-49E2-A930-E69C5579F82A

P932

Q37161532-6E028EDA-DF42-4F02-A7C4-684D97148080

P356

J.1365-2125.2008.03345.X

P1433

British Journal of Clinical Pharmacology

P1476

Co-medication of statins and C ...... n of new reimbursement policy.

@en

P2093

Espen Molden

http://www.w3.org/2001/XMLSchema#string

Helene M Devold

http://www.w3.org/2001/XMLSchema#string

Kari Furu

http://www.w3.org/2001/XMLSchema#string

Svetlana Skurtveit

http://www.w3.org/2001/XMLSchema#string

P2860

The application of prescribing indicators to a primary care prescription database in Ireland

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

FDA adverse event reports on statin-associated rhabdomyolysis.

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

The safety of statins in clinical practice.

Risk for myopathy with statin therapy in high-risk patients.

The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002.

Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003.

Switching statins in Norway after new reimbursement policy: a nationwide prescription study.

P304

234-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2008.03345.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24018383

http://www.w3.org/2001/XMLSchema#string

P698

19220274

http://www.w3.org/2001/XMLSchema#string

P932

2670381

http://www.w3.org/2001/XMLSchema#string